https://aclipsetherapeutics.com/aclipse-has-successfully-conducted-the-us-fda-pre-ind-meeting-for-m102/2024-08-29T02:02:16-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-awarded-aud-1-million-grant-from-fightmnd/2024-08-29T02:02:09-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-awarded-us-2-25-million-grant-from-medical-research-council/2024-08-29T02:02:01-04:00https://aclipsetherapeutics.com/ceocfo-magazine-interviewed-aclipse-therapeutics-ceo-raymond-houck/2024-08-29T02:01:54-04:00https://aclipsetherapeutics.com/therapeutic-development-award/2024-08-29T02:01:44-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-expands-drug-development-pipeline/2023-10-05T09:05:55-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-receives-positive-feedback-from-the-us-food-and-drug-administration-on-m107-for-the-treatment-of-gastroparesis/2024-08-29T02:09:08-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-announces-issuance-of-composition-of-matter-patent-form102-a-first-targeted-therapy-for-sporadic-als/2024-09-24T10:29:17-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-announces-publication-in-nature-reviews-drug-discovery-of-an-amyotrophic-lateral-sclerosis-review-including-m102-a-first-targeted-therapy-for-sporadic-als/2024-08-29T02:19:15-04:00https://aclipsetherapeutics.com/aclipse-therapeutics-selected-to-present-m102-als-clinical-development-program-at-prestigious-als-and-motor-neurone-disease-symposia/2024-11-10T18:39:14-05:00https://aclipsetherapeutics.com/aclipse-therapeutics-to-collaborate-with-mayo-clinic-on-phase-2-clinical-development-of-m107-for-the-treatment-of-gastroparesis/2025-11-21T16:55:08-05:00